Exagen(XGN.US) Officer Buys US$77,569.92 in Common Stock
$Exagen(XGN.US)$ Officer ABALLI JOHN purchased 40,401 shares of common stock on May 16, 2024 at an average price of $1.92 for a total value of $77,569.92.Source: Announcement What is statement of chan
Exagen Inc (XGN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Margin ...
Exagen Price Target Raised to $7.00/Share From $5.00 by Cantor Fitzgerald
Exagen Price Target Raised to $7.00/Share From $5.00 by Cantor Fitzgerald
Exagen Is Maintained at Overweight by Cantor Fitzgerald
Exagen Is Maintained at Overweight by Cantor Fitzgerald
Canto Fitzgerald: Maintaining the Exagen (XGN.US) rating, adjusted from an increase to an increase in holdings rating, and the target price was adjusted from $5.00 to $7.00.
Canto Fitzgerald: Maintaining the Exagen (XGN.US) rating, adjusted from an increase to an increase in holdings rating, and the target price was adjusted from $5.00 to $7.00.
Cantor Fitzgerald Maintains Overweight on Exagen, Raises Price Target to $7
Cantor Fitzgerald analyst Ross Osborn maintains Exagen (NASDAQ:XGN) with a Overweight and raises the price target from $5 to $7.
Exagen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 326.83% Cantor Fitzgerald $5 → $7 Maintains Overweight 09/26/2023 265.85% Cantor Fitzgerald → $
Exagen's Strong Q1 Earnings and Growth Potential Justify Buy Rating
Exagen First Quarter 2024 Earnings: Beats Expectations
Buy Rating Affirmed for Exagen Amid Strong Sales Growth and Promising Outlook
Exagen Outperforms: A Strong Buy on Rising Revenues, Margins, and Innovative Growth Prospects
Earnings Call Summary | Exagen(XGN.US) Q1 2024 Earnings Conference
The following is a summary of the Exagen, Inc. (XGN) Q1 2024 Earnings Call Transcript:Financial Performance:Exagen reported Q1 2024 total revenue of $14.4 million, driven by a strong increase in AVISE
Exagen, Inc. (XGN) Q1 2024 Earnings Call Transcript
Exagen, Inc. (XGN) Q1 2024 Earnings Call Transcript
Exagen | 10-Q: Quarterly report
Exagen Q1 2024 GAAP EPS $(0.19) Beats $(0.36) Estimate, Sales $14.415M Beat $13.095M Estimate
Exagen (NASDAQ:XGN) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.36) by 47.22 percent. This is a 56.82 percent increase over losses of $(0.44) per sh
Earnings Flash (XGN) EXAGEN Reports Q1 Revenue $14.4M, Vs. Street Est of $13.1M
08:04 AM EDT, 05/13/2024 (MT Newswires) -- Earnings Flash (XGN) EXAGEN Reports Q1 Revenue $14.4M, vs. Street Est of $13.1M
Exagen Beats Top-line and Bottom-line Estimates; Raises FY24 Outlook
Exagen: Existing Cash, Cash Equivalents Adequate to Meet Anticipated Cash Requirements Into 2026 >XGN
Exagen: Existing Cash, Cash Equivalents Adequate to Meet Anticipated Cash Requirements Into 2026 >XGN
Exagen Sees 2024 Revenue of at Least $55M>XGN
Exagen Sees 2024 Revenue of at Least $55M>XGN
Exagen Raises 2024 Guidance >XGN
Exagen Raises 2024 Guidance >XGN